At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 60 enrolled
Drug / intervention
Brimonidine Tartrate +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in a Population of Adult and Geriatric Subjects With Ocular Redness
In Brief
A Phase 3 clinical trial evaluating Brimonidine Tartrate, Vehicle, and 2 other interventions for Hyperemia. Completed, enrolled 60 participants across 1 site.
Detailed Summary
To compare the efficacy and safety of brimonidine tartrate ophthalmic solution 0.025% with its vehicle for the treatment of ocular redness in a population of adult and geriatric participants with ocular redness.
Study Details
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 2013
Enrollment StartNov 2013
Primary CompletionDec 2013
TodayJul 2026
First PostedOct 9, 2013
Enrollment StartNov 7, 2013
Primary CompletionDec 20, 2013
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 12.7 years ago
Interventions
Brimonidine Tartratedrug
Ophthalmic solution to be applied as directed.
Vehicledrug
Ophthalmic solution to be applied as directed.
Sodium Fluoresceindrug
For use as needed during the study for evaluating corneal damage.
Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USPdrug
For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.